NGHIÊN CỨU TÌNH HÌNH SỬ DỤNG VÀ TƯƠNG TÁC THUỐC TRÊN BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TÍP 2 KÈM RỐI LOẠN LIPID MÁU ĐIỀU TRỊ NGOẠI TRÚ TẠI BỆNH VIỆN TIM MẠCH THÀNH PHỐ CẦN THƠ NĂM 2025

Abstract

Background: Type 2 diabetes mellitus and dyslipidemia are common metabolic disorders that frequently coexist, requiring combination pharmacotherapy, which increases the risk of inappropriate drug use and drug–drug interactions in outpatients. Objectives: To investigate medication use patterns and determine the prevalence of drug–drug interactions in outpatients with type 2 diabetes mellitus accompanied by dyslipidemia treated at Can Tho Cardiovascular Hospital in 2025. Materials and methods: A cross-sectional descriptive study was conducted on 387 outpatient prescriptions. Drug–drug interactions were analyzed using Drugs.com, Medscape, Micromedex, and the drug interaction database of the Vietnamese Ministry of Health. Results: Metformin was the most frequently used antidiabetic drug (48.8%), and atorvastatin was the most commonly prescribed lipid-lowering agent (52.2%). According to the Drugs.com database, 282 prescriptions had drug–drug interactions (72.9%); Medscape identified interactions in 272 prescriptions (70.3%); Micromedex identified interactions in 306 prescriptions (79.1%). In contrast, the Vietnamese Ministry of Health drug interaction database did not record any clinically significant interactions. Age ≥60 years, multiple comorbidities, and the use of ≥5 drugs were associated with an increased risk of drug–drug interactions. Conclusions: Metformin and atorvastatin were the most commonly prescribed drugs, reflecting treatment practices consistent with current clinical guidelines. The high prevalence of drug–drug interactions identified by international databases highlights the necessity for routine monitoring and evaluation of drug–drug interactions in clinical practice.